Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians
详细信息 查看全文
- 作者：Pedro Rosa-Neto (1) (2)
Ging-Yuek Robin Hsiung (3)
Mario Masellis (4) (5) (6) - 刊名：Alzheimer's Research & Therapy
- 出版年：2013
- 出版时间：July 2013
- 年：2013
- 卷：5
- 期：1-supp
- 全文大小：395 KB
- 参考文献：1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT: Neuropathological alterations in Alzheimer disease. / Cold Spring Harb Perspect Biol 2011, 3:1-3.
2. Blennow K, Zetterberg H, Fagan AM: Fluid biomarkers in Alzheimer disease. / Cold Spring Harb Perspect Biol 2012, 2:1-3.
3. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. / Clin Pharmacol Ther 2001, 69:89-5.
4. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. / Lancet Neurol 2009, 9:119-28.
5. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. / Nat Rev Neurol 2010, 6:131-44.
6. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O'Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, Dearmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ: Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. / Neurology 2011, 77:2034-042.
7. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O'Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML: Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. / Ann Neurol 2008, 64:388-01.
8. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. / JAMA 2001, 286:2120-127.
9. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. / Alzheimers Dement 2011, 7:257-62.
10. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. / Science 1992, 256:184-85.
11. Hardy J: Testing times for the 'amyloid cascade hypothesis'. / Neurobiol Aging 2002, 23:1073-074.
12. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. / Nat Rev Mol Cell Biol 2007, 8:101-12.
13. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. / Brain 2008, 131:1630-645.
14. Seeman P, Seeman N: Alzheimer's disease: beta-amyloid plaque formation in human brain. / Synapse 2011, 65:1289-297.
15. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S: Aβ40 oligomers identified as a potential biomarker for the diagnosis of alzheimer's disease. / PLoS ONE 2010, 5:e15725.
16. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M: High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. / Faseb J 2010, 24:2716-726.
17. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL: Amyloid-beta oligomerization in Alzheimer dementia versus highpathology controls. / Ann Neurol 2013, 73:104-19.
18. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ: New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. / Alzheimers Dement 2013, 9:99-12.
19. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BNM: Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. / J Nucl Med 2009, 50:1464-470.
20. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative: Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid. / Alzheimers Dement 2011, 7:133-41.
21. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R: Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. / Brain 2009, 132:583-91.
22. Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB: Plasma clusterin and the risk of Alzheimer disease. / JAMA 2011, 305:1322-326.
23. Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I: Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. / J Alzheimers Dis 2012, 28:231-38.
24. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frolich L, Fr?lich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus Ch, Perneczky R, Schmidtke K, Schr?der J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J: Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. / Exp Neurol 2010, 223:366-70.
25. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL: Biochemical markers in persons with preclinical familial Alzheimer disease. / Neurology 2008, 71:85-2.
26. Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R: Elevated plasma beta-amyloid peptide Aβ(42) levels, incident dementia, and mortality in Down syndrome. / Arch Neurol 2007, 64:1007-013.
27. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C: Plasma levels of beta-amyloid (1-2) in Alzheimer's disease and mild cognitive impairment. / Neurobiol Aging 2006, 27:904-05.
28. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K: Evaluation of plasma Aβ(40) and Aβ(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. / Neurobiol Aging 2010, 31:357-67.
29. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F: Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. / Arch Neurol 2012, 69:824-31.
30. Galasko D, Golde TE: Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. / Alzheimers Res Ther 2013, 5:1-.
31. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW: A protein factor essential for microtubule assembly. / Proc Natl Acad Sci USA 1975, 72:1858-862.
32. Hall GF, Lee VM, Kosik KS: Microtubule destabilization and neurofilament phosphorylation precede dendritic sprouting after close axotomy of lamprey central neurons. / Proc Natl Acad Sci USA 1991, 88:5016-020.
33. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schr?der J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttil? T, Wallin A, J?nhagen ME, Minthon L, Winblad B, Blennow K: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. / JAMA 2009, 302:385-93.
34. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW: Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. / Neurology 2010, 74:201-09.
35. Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A: Neurochemical aftermath of amateur boxing. / Arch Neurol 2006, 63:1277-280.
36. Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B: Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. / Neurology 2006, 67:1600-604.
37. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. / Neurosci Lett 2001, 297:187-90.
38. Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P, Soininen H: CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. / Neurology 1998, 50:169-74.
39. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. / Arch Neurol 2001, 58:373-79.
40. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. / Nat Rev Neurol 2010, 6:131-44.
41. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP, CCCDTD4 participants: 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. / Can J Neurol Sci 2012,39(6 Suppl 5):S1-S8.
42. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy J-P: Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). / Can Geriatr J 2012, 15:120-26.
43. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ: Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. / BMJ 2008, 336:924.
44. Hort J, Bartos A, Pirttila T, Scheltens P: Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. / Eur J Neurol 2010, 17:90-6.
45. Kang J-H, Vanderstichele H, Trojanowski JQ, Shaw LM: Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. / Methods 2012, 56:484-93.
46. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K: Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. / Alzheimers Dement 2012, 8:65-3.
47. Reiber H: Dynamics of brain-derived proteins in cerebrospinal fluid. 2001, 310:173-86.
48. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. / Nat Med 2006, 12:856-61.
49. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM: Alzheimer's Disease Neuroimaging Initiative: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. / Alzheimers Dement 2010, 6:230-38.
50. Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW: Alzheimer's Disease Neuroimaging Initiative: Update on the magnetic resonance imaging core of the Alzheimer's Disease Neuroimaging Initiative. / Alzheimers Dement 2010, 6:212-20.
51. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K: Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. / Arch Gen Psychiatry 2004, 61:95-02.
52. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F, Chupin M, Lehéricy S, Colliot O, Hahn-Barma V, Samri D, Dubois B, Bottlaender M, Sarazin M: Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease. / Brain 2011, 134:2036-043.
53. Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, Pirttila T: Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. / Arch Neurol 2009, 66:382-89.
54. Bastard NL, Martin J-J, Vanmechelen E, Vanderstichele H, Deyn PPD, Engelborghs S: Added diagnostic value of CSF biomarkers in differential dementia diagnosis. / Neurobiol Aging 2010, 31:1867-876.
55. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YAL, van Elk EJ, Scheltens P, van der Flier WM: CSF biomarkers predict rate of cognitive decline in Alzheimer disease. / Neurology 2009, 73:1353-358.
56. Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YAL, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM: Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. / Neurology 2011, 78:47-4.
57. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. / Lancet Neurol 2006, 5:228-34.
58. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, F?rstl H, Kurz A: Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. / Mol Psychiatry 2003, 8:343-47.
59. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, Oxford Task Force Group: Biomarkers for Alzheimer's disease therapeutic trials. / Prog Neurobiol 2011, 95:579-93.
60. van Rossum IA, Vos S, Handels R, Visser PJ: Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. / J Alzheimers Disease 2010, 20:881-91.
61. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O: Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. / J Alzheimers Dis 2010, 21:1119-128.
62. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund L-O, Lannfelt L, Ingelsson M: Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. / Dement Geriatr Cogn Disord 2009, 27:458-64.
63. Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative: Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. / Neurobiol Aging 2010, 31:1443-451. 1451.e1
64. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K: Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. / Acta Neurol Scand 2003, 107:47-1.
65. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative: Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. / Arch Neurol 2010, 67:949-56.
66. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson S-E, Lindau M, Eriksdotter-Jonhagen M: Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. / Neurobiol Aging 2008, 29:1466-473.
67. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW, Alzheimer's Disease Neuroimaging Initiative: Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. / Neurobiol Aging 2010, 31:1340-354.
68. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM: CSF biomarker levels in early and late onset Alzheimer's disease. / Neurobiol Aging 2009, 30:1895-901.
69. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM: CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. / Neurology 2009, 72:1056-061.
70. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P: Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. / Neurobiol Aging 2010, 31:758-64.
71. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM, Alzheimer's Disease Neuroimaging Initiative: CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. / J Neurosci 2010, 30:2088-101.
72. Arlt S, Brassen S, Jahn H, Wilke F, Eichenlaub M, Apostolova I, Wenzel F, Thiele F, Young S, Buchert R: Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. / Eur J Nucl Med Mol Imaging 2009, 36:1090-100.
73. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative: MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. / Neurology 2009, 73:294-01.
74. Sepp?l? TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka S-K: Longitudinal changes of CSF biomarkers in Alzheimer's disease. / J Alzheimers Disease 2011, 25:583-94.
75. Abraham J-D, Calvayrac-Pawlowski S, Cobo S, Salvetat N, Vicat G, Molina L, Touchon J, Michel BF, Molina F, Verdier JM, Fareh J, Mourton-Gilles C: Combined measurement of PEDF, haptoglobin and tau in fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. / Biomarkers 2011, 16:161-71.
76. Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma H, Takubo K, Kaneko H, Kasuga K, Kakita A, Takahashi H, Bujo H, Saito Y, Nishizawa M: Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease. / Dement Geriatr Cogn Disord 2010, 30:28-2.
77. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ: Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. / Acta Neuropathol 2010, 119:669-78.
78. Santos AN, Ewers M, Minthon L, Simm A, Silber R-E, Blennow K, Prvulovic D, Hansson O, Hampel H: Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. / J Alzheimers Dis 2012, 29:171-76.
79. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rüther E, Wiltfang J: Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. / Dement Geriatr Cogn Disord 2011, 31:37-4.
80. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G: Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. / Neurology 2008, 71:1235-239.
81. Woodward M, Mackenzie IRA, Hsiung GYR, Jacova C, Feldman H: Multiple brain pathologies in dementia are common. / Eur Geriatr Med 2010, 1:259-65.
82. de Jong D, Jansen RWMM, Kremer BPH, Verbeek MM: Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. / J Gerontol A Biol Sci Med Sci 2006, 61:755-58.
83. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF: Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. / Neurology 2007, 68:1809-814.
84. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV: Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. / Arch Neurol 2009, 66:208-15.
85. Wallin ?K, Hansson O, Blennow K, Londos E, Minthon L: Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? / Int J Geriatr Psychiatry 2009, 24:638-47.
86. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, Iqbal K: Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. / J Alzheimers Dis 2011, 25:505-15.
87. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L: Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. / Acta Neurol Scand 1992, 85:103-06.
88. Tullberg M, M?nsson J-E, Fredman P, Lekman A, Blennow K, Ekman R, Rosengren LE, Tisell M, Wikkelso C: CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. / J Neurol Neurosurg Psychiatry 2000, 69:74-1.
89. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM: Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. / Ann Neurol 2003, 54:115-19.
90. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A: Subcortical vascular dementia biomarker pattern in mild cognitive impairment. / Dement Geriatr Cogn Disord 2009, 28:348-56.
91. Wallin A, Sjogren M: Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. / Mech Ageing Dev 2001, 122:1937-949.
92. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U: Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. / J Alzheimers Dis 2011, 27:665-76.
93. Rosenberg GA, Sullivan N, Esiri MM: White matter damage is associated with matrix metalloproteinases in vascular dementia. / Stroke 2001, 32:1162-168.
94. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA: Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. / Stroke 2004, 35:e159-e162.
95. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, Bresolin N, Scarpini E: Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. / J Neurol 2008, 255:539-44.
96. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. / Neurosci Lett 1995, 202:17-0.
97. Woodward M, Brodaty H, Boundy K, Ames D, Blanch G, Balshaw R: Does executive impairment define a frontal variant of Alzheimer's disease? / Int Psychogeriatr 2010, 22:1280-290.
98. Johansen KK, White LR, Sando SB, Aasly JO: Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. / Parkinsonism Relat Disord 2010, 16:307-15.
99. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T: Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. / J Neurol Neurosurg Psychiatry 2010, 81:608-10.
100. Alves G, Br?nnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes O-B, Larsen JP, Mulugeta E: CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. / J Neurol Neurosurg Psychiatry 2010, 81:1080-086.
101. Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Mu?oz E, Cho MK, Ríos J, Tolosa E: Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. / Mov Disord 2009, 24:2203-210.
102. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M: Total tau protein, phosphorylated tau (181p) protein, β-amyloid1-2, and β-amyloid1-0 in cerebrospinal fluid of patients with dementia with Lewy bodies. / Clin Chem Lab Med 2006, 44:192-95.
103. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki H-W, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J: CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. / Brain 2006, 129:1177-187.
104. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P: Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. / Biol Psychiatry 2008, 64:850-55.
105. Otto M, Lewczuk P, Wiltfang J: Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. / Methods 2008, 44:289-98.
106. Mattsson N, Blennow K, Zetterberg H: Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. / Clin Chem Lab Med 2010, 48:603-07.
107. Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K: Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. / Biomark Med 2012, 6:401-07. - 作者单位：Pedro Rosa-Neto (1) (2)
Ging-Yuek Robin Hsiung (3)
Mario Masellis (4) (5) (6)
1. McGill Centre for Studies in Aging, McGill University, 6825 LaSalle Boulevard, Verdun, Montreal, Quebec, H4H 1R3, Canada
2. Douglas Research Institute, McGill University, 6875 LaSalle Blvd, FBC room 1144, F-0105, Montréal (Verdun), QC, H4H 1R3, Canada
3. Division of Neurology, Department of Medicine, University of British Columbia, S162 - 2211 Wesbrook Mall, UBC Hospital, Vancouver, BC, V6T 2B5, Canada
4. L.C. Campbell Cognitive Neurology Research Unit, Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
5. Department of Medicine, Division of Neurology, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
6. Neurogenetics Section, Centre for Addiction and Mental Health (Queen and Ossington), 1001 Queen Street West; 30, 40, 50 and 60 White Squirrel Way; 100 and 101 Stokes Street; 80 Workman Way, Toronto, Ontario, M6J 1H4, Canada - ISSN：1758-9193
文摘
Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a rapidly evolving field. Here, we provide a review and recommendations regarding the use of fluid biomarkers in clinical practice as discussed at the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) convened in Montreal, 4 to 5 May 2012. At present, there is no consensus regarding the optimal methodology for conducting quantification of plasma amyloid-beta (Aβ) peptides. In addition, since there is insufficient evidence supporting clinical applications for plasma Aβ-peptide measures, the CCCDTD4 does not recommended plasma biomarkers either for primary care or for specialists. Evidence for CSF Aβ1-42, total tau and phosphorylated tau in the diagnosis of Alzheimer pathology is much stronger, and can be considered at the tertiary care level for selected cases to improve diagnostic certainty, particularly in those cases presenting atypical clinical features.